On Day Two of 2024's LSX World Congress, we’ll hear about the biotech/biopharma IPO market, the 2024 US Presidential election, and about the future of digital health.
Executives from AstraZeneca, Takeda, Merck, Roche, Johnson & Johnson, Bayer, Teva, Otsuka, and Lilly will all weigh in throughout the day.
AstraZeneca is facing some pushback as it tries to upgrade anticoagulant antidote drug Andexxa to full approval in the US
At LSX in Boston last month, editor-in-chief Jonah Comstock caught up with Dr Tadaaki Taniguchi, chief medical officer at Astellas Pharmaceuticals to talk a bit about the company and some r
Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
IN THIS ISSUE: The 2024 US Presidential race is nearing its end, but what does that mean for pharma?
In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.
In this podcast episode, Jesse Mendelsohn and Nicole Raleigh discuss what the future might hold for pharma under a second Trump Administration
The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges and opportunities.
9th Liquid Biopsy for Precision Oncology Summit | February 18-20, 2025 | San Diego, CA | FREE* to Attend for Biopharma
The pivotal shift in biopharma priorities is steering towards enhancing sustainability measures for drug development.
